Improving Coronary Vascular Health in Women

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age45-75
SponsorMassachusetts General Hospital

About this trial

Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed. We are conducting a study randomizing women with HIV and either diabetes, chronic kidney disease, or both to health education alone or to health education plus referral to see either an Endocrinologist or a Nephrologist in a subspecialty clinic for consideration of treatment with medication in a class known as sodium glucose transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors are clinically approved for use in patients with diabetes or chronic kidney disease but have been shown to be underutilized in people with HIV. One of our key analytic aims will be to test if SGLT2 inhibitor therapy results in improved blood flow through the large and small coronary arteries among women with HIV and either diabetes, chronic kidney disease, or both but who have no history of myocardial infarction. A second aim will be to test if subspecialty clinic referral (with or without SGLT2 inhibitor therapy prescription) results in improved blood flow through the large and small coronary arteries among the same group.

Eligibility criteria

Qualifiers

female sex-at-birth

self-report of HIV on stable antiretroviral therapy ≥180 days

age 45 -75 years

at least 1 of the following 3 conditions: i) type 2 diabetes mellitus ii) estimated glomerular filtration rate 30-60 ml/min/1.73 m2 iii) urine albumin to creatinine ratio >30 mg/g

Disqualifiers

current SGLT2 inhibitor use

known allergy to SGLT2 inhibitor use

type 1 diabetes or ketoacidosis prone diabetes (diabetes with a history of ketoacidosis)

self-reported history of polycystic kidney disease

Trial design

Treatments tested in this trial

  • Health Education
  • Subspecialty clinic referral

Treatment groups

80 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Massachusetts General Hospital

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator